Published in Blood Weekly, February 12th, 2004
CR-BSIs are one of the most common hospital-acquired infections.
Dalbavancin administered once weekly for the treatment of CR-BSI was superior to vancomycin given twice daily at the study's primary endpoint, the combined clinical and microbiological response.
This is the first time any Gram-positive injectable antibiotic has been shown to be superior to vancomycin in a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.